bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
25 Julho 2023 - 9:00AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced it will
hold a conference call to discuss second quarter 2023 financial
results and provide a commercial update on Tuesday, August 8 at
8:00 a.m. ET. In addition to providing an overview of the business,
the conference call will highlight the Company’s ongoing commercial
launches of SKYSONA® and ZYNTEGLO® and the market opportunity for
lovo-cel.
To access the call via telephone, please register at this link
https://register.vevent.com/register/BI4fa1d86317c74333813f6827624e43ae
to receive a dial in number and unique PIN to access the live
conference call.
The live webcast of the call may be accessed by visiting the
“Events & Presentations” page within the Investors & Media
section of the bluebird website at http://investor.bluebirdbio.com.
A replay of the webcast will be available on the bluebird website
for 90 days following the event.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
With a dedicated focus on severe genetic diseases, bluebird has
industry-leading programs for sickle cell disease, β-thalassemia
and cerebral adrenoleukodystrophy and is advancing research to
apply new technologies to these and other diseases. We custom
design each of our therapies to address the underlying cause of
disease and have developed in-depth and effective analytical
methods to understand the safety of our lentiviral vector
technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo
gene therapy data set in the world—setting the standard for the
industry. Today, bluebird continues to forge new paths, combining
our real-world experience with a deep commitment to patient
communities and a people-centric culture that attracts and grows a
diverse flock of dedicated birds.
For more information, visit bluebirdbio.com or follow us
on social media at @bluebirdbio, LinkedIn,
Instagram and YouTube.
bluebird bio, ZYNTEGLO and SKYSONA are registered trademarks of
bluebird bio, Inc. All rights reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230725829182/en/
Investors:
Courtney O’Leary, 978-621-7347 coleary@bluebirdbio.com
Media:
Jess Rowlands, 857-299-6103 jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
bluebird bio (NASDAQ:BLUE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024